Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Change in Accured Expenses (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Change in Accured Expenses for 3 consecutive years, with -$2.0 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Change in Accured Expenses fell 125.24% year-over-year to -$2.0 million, compared with a TTM value of $8.7 million through Dec 2021, up 8.57%, and an annual FY2024 reading of -$756000.0, down 119.2% over the prior year.
  • Change in Accured Expenses was -$2.0 million for Q4 2021 at Black Diamond Therapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.8 million in Q4 2020 and bottomed at -$2.6 million in Q4 2019.
  • Average Change in Accured Expenses over 3 years is $1.3 million, with a median of $755500.0 recorded in 2019.
  • The sharpest move saw Change in Accured Expenses plummeted 146.98% in 2020, then soared 1806.86% in 2021.
  • Year by year, Change in Accured Expenses stood at -$2.6 million in 2019, then soared by 405.26% to $7.8 million in 2020, then plummeted by 125.24% to -$2.0 million in 2021.
  • Business Quant data shows Change in Accured Expenses for BDTX at -$2.0 million in Q4 2021, $3.3 million in Q3 2021, and $4.5 million in Q2 2021.